

## **CogENT Therapeutics<sup>™</sup>, LLC Announces US Launch of the XeroGel<sup>™</sup> Nasal/Epistaxis Pack**

HAYWARD, Ca., December 3, 2012 -- CogENT Therapeutics, LLC, an innovative ear, nose and throat medical device company, announced today the US launch of its first commercial product, the XeroGel nasal/epistaxis pack. XeroGel provides a unique combination of inherent hemostatic properties, turgidity during wound healing and thorough, consistent dissolution to enhance patient comfort during follow up exams.

XeroGel is supplied as a dry sponge that is inserted into the nasal cavity to prevent adhesions while the inherent hemostat helps minimize post-surgical bleeding. In the ER, its consistency lends itself to easier placement than the stiff nasal tampons traditionally used for nosebleeds. Upon placement, the pack absorbs fluid and conforms to the treatment site in order to minimize bleeding, prevent adhesions to mucosal surfaces, and aid in the natural healing process. XeroGel gradually dissolves to a mucus-like consistency that is cleared via nasal outflow; any residual material resident at follow-up may be removed through gentle aspiration and irrigation.

Nadim Bikhazi, MD, ENT surgeon and Board President of Ogden Clinic in Ogden, Utah, remarked "We have used XeroGel in numerous FESS [Functional Endoscopic Sinus Surgery] procedures to date and found that it provides a conformable, cohesive barrier to adhesions and dissolves to leave little to no material remaining at our weekly follow-up. We also see great potential for XeroGel to improve the treatment of epistaxis in patients that tend to be difficult to treat, such as the elderly, hypertensive patients, or those on anticoagulant medications".

"Many commonly used nasal packs produce suboptimal outcomes and the ideal solution for post-operative patient care following nasal/sinus surgery remains elusive. The XeroGel nasal/epistaxis pack was thoughtfully designed to address the need for improved post surgical management of patients by the ENT community, as well as to provide improved comfort to patients undergoing these procedures. We look forward to adding XeroGel to the ENT surgeon's tool kit," said Suresh Pai, CEO of CogENT Therapeutics.

### **About CogENT Therapeutics, LLC**

CogENT Therapeutics, LLC ([www.cogent-tx.com](http://www.cogent-tx.com)) is a privately held company pioneering innovative biomaterial and device solutions focused on improving the lives of patients suffering from ear, nose and throat (ENT) disorders. CogENT Therapeutics can be contacted at 650.450.4956 or [infoandsales@cogent-tx.com](mailto:infoandsales@cogent-tx.com).